Also from this source

You just read:

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

News provided by

Takeda Pharmaceutical Company Limited

Jun 03, 2018, 08:30 ET